Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival.

Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M.

Cancer Prev Res (Phila). 2011 Oct;4(10):1609-16. doi: 10.1158/1940-6207.CAPR-10-0361. Epub 2011 Jul 27.

2.

A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.

Meshkat B, Prichard RS, Al-Hilli Z, Bass GA, Quinn C, O'Doherty A, Rothwell J, Geraghty J, Evoy D, McDermott EW.

Breast. 2015 Jun;24(3):278-82. doi: 10.1016/j.breast.2015.02.032. Epub 2015 Mar 11.

PMID:
25771080
3.

Interval Breast Cancer Versus Screen-Detected Cancer: Comparison of Clinicopathologic Characteristics in a Single-Center Analysis.

Bellio G, Marion R, Giudici F, Kus S, Tonutti M, Zanconati F, Bortul M.

Clin Breast Cancer. 2017 Nov;17(7):564-571. doi: 10.1016/j.clbc.2017.04.001. Epub 2017 Apr 11.

PMID:
28456487
4.

Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes.

Kim J, Lee S, Bae S, Choi MY, Lee J, Jung SP, Kim S, Choe JH, Kim JH, Kim JS, Lee JE, Nam SJ, Yang JH.

Breast Cancer Res Treat. 2012 Jan;131(2):527-40. doi: 10.1007/s10549-011-1836-0. Epub 2011 Oct 30.

PMID:
22042364
5.

Infiltrating lobular carcinoma of the breast detected by screening.

Schroën AM, Wobbes T, van der Sluis RF.

Br J Surg. 1998 Mar;85(3):390-2.

PMID:
9529500
6.

Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML.

PLoS One. 2011;6(8):e23543. doi: 10.1371/journal.pone.0023543. Epub 2011 Aug 12.

7.

Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics.

Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA.

Eur J Surg Oncol. 2015 Oct;41(10):1417-22. doi: 10.1016/j.ejso.2015.07.002. Epub 2015 Jul 17.

PMID:
26253193
8.

Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.

Seneviratne S, Lawrenson R, Scott N, Kim B, Shirley R, Campbell I.

PLoS One. 2015 Apr 7;10(4):e0123523. doi: 10.1371/journal.pone.0123523. eCollection 2015.

9.

Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers.

Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M.

Eur J Cancer Prev. 2013 Jan;22(1):21-8. doi: 10.1097/CEJ.0b013e328354d324.

PMID:
22584215
10.

Breast cancer screening at the Breast Examination Center of Harlem.

Manning AT, Eaton A, Azu M, Sampson M, Patil S, Godfrey D, Beesen AA, Liberman L, Gemignani ML.

Ann Surg Oncol. 2015;22(6):2026-33. doi: 10.1245/s10434-014-4240-2. Epub 2014 Dec 2.

11.

Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.

Walker MJ, Mirea L, Cooper K, Nabavi M, Glendon G, Andrulis IL, Knight JA, O'Malley FP, Chiarelli AM.

Fam Cancer. 2014 Jun;13(2):163-72. doi: 10.1007/s10689-013-9689-9.

PMID:
24097051
12.

Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.

Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, Cortese G, Farina M, Vitelli C.

Ann Surg Oncol. 2012 Apr;19(4):1107-14. doi: 10.1245/s10434-011-1907-9. Epub 2011 Sep 13.

PMID:
21913022
13.

Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML.

Breast Cancer Res Treat. 2014 Jan;143(1):189-201. doi: 10.1007/s10549-013-2796-3. Epub 2013 Dec 4.

14.

Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA.

J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203.

PMID:
16106024
15.

Risk for distant recurrence of breast cancer detected by mammography screening or other methods.

Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J.

JAMA. 2004 Sep 1;292(9):1064-73.

PMID:
15339900
16.

Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization.

Günther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schröder W, Tietze L.

J Pathol. 2001 Jan;193(1):40-7.

PMID:
11169514
17.

Breast MRI: opportunities and challenges.

Day D.

Minn Med. 2009 Dec;92(12):45-8.

PMID:
20092173
18.

Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.

Chuang SL, Chen SL, Yu CP, Chang KJ, Yen AM, Chiu SY, Fann JC, Tabár L, Stephen DW, Smith RA, Chen HH.

APMIS. 2014 Aug;122(8):699-707. doi: 10.1111/apm.12294. Review.

PMID:
25046200
19.

ESPL1 is a candidate oncogene of luminal B breast cancers.

Finetti P, Guille A, Adelaide J, Birnbaum D, Chaffanet M, Bertucci F.

Breast Cancer Res Treat. 2014 Aug;147(1):51-9. doi: 10.1007/s10549-014-3070-z. Epub 2014 Aug 3.

PMID:
25086634
20.

The consequence of undertreating breast cancer in the elderly.

Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL.

J Am Coll Surg. 2001 Jun;192(6):698-707.

PMID:
11400963

Supplemental Content

Support Center